Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 19/20 | 0.76 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | C1R | P00736 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6082809 | 0.86 | ELANE (1.00) | ELANEMEN1KMT2AC1R | |
| SCHEMBL6136297 | 0.85 | ELANE (0.83) | ELANEMEN1KMT2AC1R | |
| SCHEMBL692733 | 0.85 | ELANE (0.81) | ELANEMEN1KMT2AC1R | |
| SCHEMBL29405904 | 0.85 | ELANE (0.81) | ELANEMEN1KMT2AC1R | |
| SCHEMBL272505 | 0.83 | ELANE (0.82) | ELANEMEN1KMT2AC1R | |
| SCHEMBL4566025 | 0.82 | ELANE (0.80) | ELANEMEN1KMT2AC1R | |
| SCHEMBL29444886 | 0.82 | ELANE (0.76) | ELANEMEN1KMT2AC1R | |
| SCHEMBL692829 | 0.82 | ELANE (0.76) | ELANEMEN1KMT2AC1R | |
| SCHEMBL10550516 | 0.82 | ELANE (1.00) | ELANEMEN1KMT2AC1R | |
| SCHEMBL4408698 | 0.82 | ELANE (0.70) | ELANEMEN1KMT2AC1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210338674-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING DISORDERS ASSOCIATED WITH THE 5-HT1A AND 5-HT2A RECEPTORS | ACHE LABORATORIOS FARMACEUTICOS SA (BR) | 2021-11-04 | — | — | US | disclosed |
| US-20170292022-A1 | Sulfone polymer composition | SOLVAY SPECIALTY POLYMERS USA, LLC (US) | 2017-10-12 | — | — | US | disclosed |
| US-9326984-B2 | Compounds and pharmaceutical compositions for treating disorders associated with the 5-HT1A and 5-HT2A receptors | ACHE LABORATORIOS FARMACEUTICOS S.A. (BR) | 2016-05-03 | — | — | US | disclosed |
| US-20160008360-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING DISORDERS ASSOCIATED WITH THE 5-HT1A AND 5-HT2A RECEPTORS | ACHE LAB FARMACEUTICOS SA (BR) | 2016-01-14 | — | — | US | disclosed |
| US-9173869-B2 | Mediators of hedgehog signaling pathways, compositions and uses related thereto | CURIS, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-9173869-B2 | Mediators of hedgehog signaling pathways, compositions and uses related thereto | CURIS, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-9169218-B2 | Compounds and pharmaceutical compositions for treating disorders associated with the 5-HT1A and 5-HT2A receptors | ACHE LABORATORIOS FARMACEUTICOS S.A. (BR) | 2015-10-27 | — | — | US | disclosed |
| EP-2619187-B1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING DISORDERS ASSOCIATED WITH THE 5-HT1A AND 5-HT2A RECEPTORS | ACHÉ LABORATÓRIOS FARMAC UTICOS S A (BR) | 2015-03-04 | — | — | EP | disclosed |
| US-20140336199-A1 | Compounds and Pharmaceutical Compositions for Treating Disorders Associated With the 5-HT1A and 5-HT2A Receptors | ACHE LABORATORIOS FARMACEUTICOS S.A., ATC Trustees Abbot Building, 2nd FLoor, Road Town (BR) | 2014-11-13 | — | — | US | disclosed |
| US-20140303179-A1 | Compounds and Pharmaceutical Compositions for Treating Disorders Associated With the 5-HT1A and 5-HT2A Receptors | ACHÉ INTERNATIONAL (BVI) LTD. (VG) | 2014-10-09 | — | — | US | disclosed |
| US-20070021493-A1 | Mediators of hedgehog signaling pathways, compositions and uses related thereto | CURIS, INC. (US) | 2007-01-25 | — | — | US | disclosed |
| EP-1743891-A1 | Heterocyclic compounds and methods for modulating CXCR3 function | ChemoCentryx Inc (US) | 2007-01-17 | — | — | EP | disclosed |
| EP-1717230-A1 | FUSED-RING 4-OXOPYRIMIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-02 | — | — | EP | disclosed |
| EP-1646615-A1 | PYRIMIDINE DERIVATIVES AS MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | Vertex Pharmaceuticals Incorporated (US) | 2006-04-19 | — | — | EP | disclosed |
| EP-1586446-A1 | LAMINATE FILM | Teijin Dupont Films Japan Limited (JP) | 2005-10-19 | — | — | EP | disclosed |
| US-20050182045-A1 | Fused ring 4-oxopyrimidine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| US-20050059687-A1 | Modulators of ATP-Binding Cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED | 2005-03-17 | — | — | US | disclosed |
| WO-2004111014-A1 | PYRIMIDINE DERIVATIVES AS MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-12-23 | — | — | WO | disclosed |
| US-4841051-A | ALPHA-RECEPTOR BLOCKING AGENTS | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1989-06-20 | — | — | US | disclosed |
| EP-0228605-A1 | Phenylpiperazine derivatives | Nippon Kayaku Kabushiki Kaisha (JP) | 1987-07-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210338674-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING DISORDERS ASSOCIATED WITH THE 5-HT1A AND 5-HT2A RECEPTORS | HTR2A, HTR5A, HTR2C | ELANE 4671/4885MEN1 3395/4885KMT2A 961/4885 |
| US-20070021493-A1 | Mediators of hedgehog signaling pathways, compositions and uses related thereto | SHH, SMO, GLI1 | ELANE 4341/4885MEN1 1518/4885KMT2A 2765/4885 |
| US-20160008360-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING DISORDERS ASSOCIATED WITH THE 5-HT1A AND 5-HT2A RECEPTORS | HTR2A, HTR5A, HTR2C | ELANE 4664/4885MEN1 3256/4885KMT2A 979/4885 |
| US-20140303179-A1 | Compounds and Pharmaceutical Compositions for Treating Disorders Associated With the 5-HT1A and 5-HT2A Receptors | HTR5A, HTR2A, HTR1A | ELANE 4766/4885MEN1 3434/4885KMT2A 728/4885 |
| US-20050182045-A1 | Fused ring 4-oxopyrimidine derivative | HRH4, HRH2, HRH3 | ELANE 4447/4885MEN1 2904/4885KMT2A 528/4885 |
| US-20140336199-A1 | Compounds and Pharmaceutical Compositions for Treating Disorders Associated With the 5-HT1A and 5-HT2A Receptors | HTR5A, HTR2A, HTR2C | ELANE 4752/4885MEN1 3489/4885KMT2A 826/4885 |
| US-20050059687-A1 | Modulators of ATP-Binding Cassette transporters | CFTR, ABCB1, ABCC2 | ELANE 1025/4885MEN1 4698/4885KMT2A 4344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.